FDAsafety guidance77% confidence
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
On July 23-24, 2026, the Committee will discuss bulk drug substances being considered for inclusion on the 503A Bulks List.
Supporting Context
- Therapeutic area
- Neurology · Parkinson's Disease
- Sub-indication
- General
Related signal: Aurobindo Pharma's ANDA216537 for Carbidope and Levodopa Receives AP Status